Parallax Reaffirms Previously Released Statement
18 March 2020 - 9:14PM
InvestorsHub NewsWire
Parallax Reaffirms Previously
Released Statement
FDA Approved VT-1000 Qualitative and
Quantitative Analyzer
NEW YORK, NY -- March 18, 2020 -- InvestorsHub NewsWire
-- Parallax Health Sciences,
Inc. (PRLX)
(''Parallax'' or the ''Company''), an outcome-driven connected
healthcare company, today announced in a statement that it
reaffirms its plan to manufacture the Company’s VT-1000 qualitative
and quantitative immunoassay analyzer for medical use and has
already previously been approved through a 510(K) with the U.S.
Federal Drug Administration, (“FDA”).
“We are committed to our diagnostics testing equipment in the
areas of infectious disease, cardiac related and substances of
abuse,” stated Paul Arena, Chief Executive Officer of Parallax
Health Sciences, Inc. Mr. Arena continued, “We are further
committed to delivering a cost effective and dependable solution
for testing coronavirus, (“Covid-19”) into the healthcare community
during a time when such testing is in high-demand worldwide.”
About Parallax Diagnostics
Parallax Diagnostics is a bio-medical company and wholly owned
subsidiary of Parallax Health Sciences, Inc. Parallax Diagnostics
owns a line of 26 FDA approved, Point of Care diagnostic tests on a
single platform in the area of infectious disease, cardiac, medical
conditions, drugs of abuse, and pregnancy. Parallax
Diagnostics is developing a novel, handheld diagnostic testing
system that is simple, rapid and elegant, offering the potential to
transform the diagnostic landscape by transitioning critical tests
from the centralized lab directly to the hands of the physician or
clinicians. Our focus is on tests that detect and/or monitor
infectious diseases.
About Parallax Health Sciences
Parallax Health Sciences is a leading-edge technology,
outcome-driven telehealth company that allows for cost-effective
remote diagnosis, treatment and monitoring of patients through
proprietary platforms of integrated products and services. The
Company's interoperable novel applications provide patients
point-of-care testing and monitoring with information communicated
via internet-based mobile phone applications that are agnostic as
to operating system and are built on highly sophisticated data
analytics. Information is retrieved real-time by physicians who are
monitoring patients with chronic diseases or through biometric
feedback for health-related behavior modification, and is automated
for integration into electronic health records. The Company's
products and offerings capitalize on the digital transformation in
healthcare for improved patient compliance, diagnosis and
treatment, and support healthcare system cost savings and
efficiencies. For more information, please visit www.parallaxhealthsciences.com or www.parallaxcare.com.
Forward-Looking Statements
This release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
All statements regarding our expected future financial position,
results of operations, cash flows, financing plans, business
strategy, products and services, competitive positions, growth
opportunities, plans and objectives of management for future
operations, as well as statements that include words such as
"anticipate," "if," "believe," "plan," "estimate," "expect,"
"intend," "may," "could," "should," "will," and other similar
expressions are forward-looking statements. All forward-looking
statements involve risks, uncertainties and contingencies, many of
which are beyond our control, which may cause actual results,
performance, or achievements to differ materially from anticipated
results, performance, or achievements. Factors that may cause
actual results to differ materially from those in the
forward-looking statements include those set forth in our Form 10-K
and other reports filed with the SEC. We are under no obligation to
(and expressly disclaim any such obligation to) update or alter our
forward-looking statements, whether as a result of new information,
future events or otherwise.
Investor Contact:
Paul Arena, CEO
paul@parallaxcare.com
Parallax Health Sciences (CE) (USOTC:PRLX)
Historical Stock Chart
From May 2024 to Jun 2024
Parallax Health Sciences (CE) (USOTC:PRLX)
Historical Stock Chart
From Jun 2023 to Jun 2024